SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Eli Lilly's headquarters in Indianapolis
Manufacturing
Lilly Unveils Second Facility in Manufacturing Push, Naming Texas as Site of New $6.5B Plant
Lilly expects to open 615 high-wage roles in Texas in connection with its new facility, plus around 4,000 construction roles.
September 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Biogen's headquarters in Cambridge, Massachusetts
Spinal muscular atrophy
Biogen Receives Surprise FDA Rejection for High Dose Spinraza
The regulatory action marks the second rejection for a spinal muscular atrophy therapy this week after Scholar Rock’s apitegromab was issued a complete response letter on Tuesday, similarly on manufacturing grounds.
September 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
The FDA is hoping to repurpose GSK’s Wellcovorin for cerebral folate deficiency; Pfizer acquired fast-moving weight-loss startup Metsera for nearly $5 billion after suffering a hat trick of R&D failures; psychedelics are primed for M&A action and Eli Lilly may be next in line; RFK Jr.’s revamped CDC advisory committee met last week with confounding results; and Stealth secured its Barth approval.
September 24, 2025
 · 
2 min read
 · 
Heather McKenzie
Immunization of kids abstract concept vector illustration. Family doctor vaccinates a child in walk-in clinic, preventive care for kids, medicine sector, make an injection abstract metaphor.
Vaccines
As Kennedy Takes Aim at Childhood Vaccines, a History of Merck’s ProQuad
While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on Merck’s business, the company said the removal of choice for healthcare providers is “concerning.”
September 23, 2025
 · 
6 min read
 · 
Annalee Armstrong
Drug or medicine dose adjustment. Dose regulation and overdose. Titration of medicine dosage. Overmedication and prescribed dose. Drug rejection.
Spinal muscular atrophy
Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug
In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this site have previously been investigated by the regulator.
September 23, 2025
 · 
2 min read
 · 
Tristan Manalac
JHVEPhoto/GettyImages
Government
FDA Revives Decades-Dormant Drug as Potential Autism Treatment
The agency also pointed to the use of Tylenol and other acetaminophen products during pregnancy as being potentially linked to neurological and developmental defects in children, following a press conference Monday in which President Donald Trump did the same.
September 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration showing hurdles along a path ending in an arrow
Regulatory
After FDA Rejection, Lexicon’s Type 1 Diabetes Drug Hit With Another Regulatory Delay
An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases of diabetic ketoacidosis.
September 23, 2025
 · 
1 min read
 · 
Tristan Manalac
Modern halftone collage. Concept of teamwork, problem solving together, business direction, collaborate to win,achieve success. Business creative illustration for web banner, marketing material, business presentation. Vector illustration
Rare diseases
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease
By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William Blair.
September 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Weight loss scale and pile of money/Tayl
Manufacturing
To Compete in Obesity, Late Entrants Invest Early in Manufacturing
Small and large drugmakers alike have made big, proactive moves to secure the production capacity that will be vital to serving the weight loss market.
September 23, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS